Bafna Pharmaceuticals (BOM:532989) Cyclically Adjusted PB Ratio: (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532989 Bafna Pharmaceuticals Ltd BOM:532989
57 GF Score
Price ₹290.40
GF Value ₹87.17
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bafna Pharmaceuticals  (BOM:532989) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Bafna Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Bafna Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.83 3.02

Bafna Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4.39 0.00 3.02 0.00

BOM:532989 vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bafna Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


BOM:532989
57GF Score
Bafna Pharmaceuticals Ltd BOM:532989
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Bafna Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Bafna Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Bafna Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201209 23.350 82.244 47.515
201212 0.000 83.774 0.000
201303 36.156 85.687 70.617
201403 36.909 91.425 67.564
201503 38.475 97.163 66.271
201603 30.956 102.518 50.535
201703 22.869 105.196 36.383
201803 16.033 109.786 24.441
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 8.056 118.202 11.406
201906 0.000 120.880 0.000
201909 6.907 123.175 9.385
201912 0.000 126.235 0.000
202003 21.536 124.705 28.902
202006 0.000 127.000 0.000
202009 22.504 130.118 28.945
202012 0.000 130.889 0.000
202103 23.999 131.771 30.480
202106 0.000 134.084 0.000
202109 27.464 135.847 33.834
202112 0.000 138.161 0.000
202203 26.194 138.822 31.578
202206 0.000 142.347 0.000
202209 27.832 144.661 32.199
202212 0.000 145.763 0.000
202303 31.051 146.865 35.384
202306 0.000 150.280 0.000
202309 34.818 151.492 38.464
202312 0.000 152.924 0.000
202403 34.173 153.035 37.371
202406 0.000 155.789 0.000
202409 34.981 157.882 37.080
202412 0.000 158.323 0.000
202503 35.850 157.552 38.081
202506 0.000 159.755 0.000
202509 38.564 162.289 39.768
202512 0.000 163.281 0.000
202603 40.645 164.272 41.408
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Bafna Pharmaceuticals (BOM:532989) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹290.40 is trading 233.1% above its estimated GF Value™ of ₹87.17. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:532989:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹87.17 vs. price of ₹290.40 (233.1% above fair value)
  • GF Score™: 57/100 with 9 warning signs

No single metric tells the full story. See the BOM:532989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bafna Pharmaceuticals Business Description

Other Exchanges BAFNAPH:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
57GF Score

Get the complete analysis for BOM:532989

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹290.40
Price
₹87.17
GF Value